The current global epidemic of hypertension is not a disease in and of itself but rather
a significant risk factor for serious cardiovascular conditions such as peripheral artery disease,
heart failure, myocardial infarction, and stroke. Although many medications that work through
various mechanisms of action are available on the market in conventional formulations to treat
hypertension, these medications face significant difficulties with their bioavailability, dosing,
and associated side effects, which significantly reduces the effectiveness of their therapeutic
interventions. Numerous studies have shown that nanocarriers and nanoformulations can minimize
the toxicity associated with high doses of the drug while greatly increasing the drug's bioavailability
and reducing the frequency of dosing.
This review sheds light on the difficulties posed by traditional antihypertensive formulations and
highlights the necessity of oral nanoparticulate systems to solve these issues. Because hypertension
has a circadian blood pressure pattern, chronotherapeutics can be very important in treating
the condition. On the other hand, nanoparticulate systems can be very important in managing
hypertension.